{
    "N/R/U": null,
    "Applicant": "Novartis Pharmaceuticals Corporation",
    "BLA Number": "761128",
    "Proprietary Name": "Adakveo",
    "Proper Name": "crizanlizumab-tmca",
    "BLA Type": "351(a)",
    "Strength": "100MG/10ML (10MG/ML)",
    "Dosage Form": "Injection",
    "Route of Administration": "Intravenous",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "November 15, 2019",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "1244",
    "Product Number": "001",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": "November 15, 2026",
    "drug": [
        {
            "name": "crizanlizumab-tmca",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15271"
        }
    ]
}